Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             42 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A new formulation of praziquantel to achieve schistosomiasis elimination Yang, Guo-Jing

23 7 p. 774-776
artikel
2 A new network for pathogen surveillance Burki, Talha

23 7 p. 792-793
artikel
3 An exciting time for antifungal therapy The Lancet Infectious Diseases,

23 7 p. 763
artikel
4 Balancing adjunctive therapy for tuberculosis treatment Ndjeka, Norbert

23 7 p. 771-772
artikel
5 Brazil tackles its tuberculosis burden Bagcchi, Sanjeet

23 7 p. 790
artikel
6 Breakthrough treatments for Ebola virus disease, but no access—what went wrong, and how can we do better? Torreele, Els

23 7 p. e253-e258
artikel
7 Can a single dose of Modified Vaccinia Ankara-Bavarian Nordic vaccine protect against mpox? Ogoina, Dimie

23 7 p. 768-769
artikel
8 Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis Garcia-Prats, Anthony J

23 7 p. 778-780
artikel
9 Correction to Lancet Infect Dis 2023; published online May 4. https://doi.org/10.1016/S1473-3099(23)00121-4
23 7 p. e227
artikel
10 Economic evaluations of interventions to prevent and control health-care-associated infections: a systematic review Rice, Stephen

23 7 p. e228-e239
artikel
11 Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system Lewnard, Joseph A

23 7 p. 806-815
artikel
12 Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study Bertran, Marta

23 7 p. 828-835
artikel
13 Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trial N'Goran, Eliézer K

23 7 p. 867-876
artikel
14 Engaging pharmacists and medicine vendors in antimicrobial stewardship in LMICs Oga-Omenka, Charity

23 7 p. 786-787
artikel
15 Highly multidrug-resistant Gram-negative bacterial infections in war victims in Ukraine, 2022 Ljungquist, Oskar

23 7 p. 784-786
artikel
16 How to survive to the COVID-19 pandemic Bisbas, Georgia

23 7 p. 797
artikel
17 Imprinted hybrid immunity against XBB reinfection Boyton, Rosemary J

23 7 p. 764-765
artikel
18 Infectious disease surveillance update Zwizwai, Ruth

23 7 p. 793
artikel
19 James Banta Bagcchi, Sanjeet

23 7 p. 795
artikel
20 James Ward—tackling STIs in Indigenous Australians Kirby, Tony

23 7 p. 796
artikel
21 Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study Chemaitelly, Hiam

23 7 p. 816-827
artikel
22 Maintaining a robust pipeline of antibiotics Jesudason, Timothy

23 7 p. 791
artikel
23 Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection Carr, Edward J

23 7 p. 781-784
artikel
24 Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data Wilkins, Deidre

23 7 p. 856-866
artikel
25 Nirsevimab-resistant respiratory syncytial virus strains are rare but there Peeples, Mark E

23 7 p. 773-774
artikel
26 Participatory research for improving Inuit health Venkatesan, Priya

23 7 p. 788
artikel
27 Prevention of long COVID: progress and challenges Al-Aly, Ziyad

23 7 p. 776-777
artikel
28 Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial Wolfensberger, Aline

23 7 p. 836-846
artikel
29 Progress in preventing non-ventilator-associated hospital-acquired pneumonia Klompas, Michael

23 7 p. 769-771
artikel
30 Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study Tan, Celine Y

23 7 p. 799-805
artikel
31 Real-world use of nirmatrelvir–ritonavir: who benefits? Molina, Kyle C

23 7 p. 765-767
artikel
32 Redefining Clostridioides difficile infection antibiotic response and clinical outcomes Gonzales-Luna, Anne J

23 7 p. e259-e265
artikel
33 Research in brief Devi, Sharmila

23 7 p. 794
artikel
34 Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial Cross, Gail B

23 7 p. 847-855
artikel
35 Serpiginous-like choroiditis in ocular tuberculosis Tyagi, Mudit

23 7 p. 877
artikel
36 Standard of care for viral haemorrhagic fevers (VHFs): a systematic review of clinical management guidelines for high-priority VHFs Rigby, Ishmeala

23 7 p. e240-e252
artikel
37 Statin use in people living with HIV Venkatesan, Priya

23 7 p. 789
artikel
38 The dangers of using large language models for peer review Donker, Tjibbe

23 7 p. 781
artikel
39 The ups and downs of observational vaccine research Barda, Noam

23 7 p. 767-768
artikel
40 Tracheobronchial tuberculosis and its sequelae in children and adolescents Yang, Ming-Jin

23 7 p. 786
artikel
41 Trichophyton rubrum-induced Majocchi's granuloma in an immunocompromised patient Vetsiou, Evangelia

23 7 p. 878
artikel
42 “West” vs “Rest”—Epidemic Orientalism Sherwood-Martin, Hollie

23 7 p. 798
artikel
                             42 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland